Company to showcase its innovative
Alzheimer's, Parkinson's and ALS programs
TORONTO and CAMBRIDGE, MA, April
23, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX:
PMN) (OTCQB: ARFXF), a biotechnology company focused on the
discovery and development of antibody therapeutics selectively
targeting toxic oligomers implicated in the development of
neurodegenerative diseases, announced that it will participate in
the Think Equity Investor Conference being held on May 2, 2019 at the Mandarin Oriental Hotel in
New York.
Eugene Williams, ProMIS'
Executive Chairman will provide overviews of its novel drug
discovery and development programs for Alzheimer's disease,
Parkinson's disease and ALS (amyotrophic lateral sclerosis) at
10:30 am ET, in the Lotus West Room.
In his talk Mr. Williams will also underline how the evaluation of
novel biomarkers in patients will significantly accelerate drug
development in neurodegenerative diseases. The video webcast and
slides of Mr. Williams' presentation will be available through the
following link http://wsw.com/webcast/thinkequity/arfxf/. The
webcast will be archived for 90 days following the event through
the same link.
About ProMIS' Platform Technology
Numerous studies
show that a common root cause of neurodegenerative diseases is the
toxic oligomer, a misfolded protein that derives from naturally
occurring proteins in the brain. Using its novel drug discovery
platform, ProMIS can uniquely and selectively target the toxic
oligomer, filling a critical gap for drug developers as traditional
approaches to developing antibodies are unable to isolate and
target the toxic oligomer with adequate precision. This proprietary
platform can identify targets to produce, test and advance antibody
candidates quickly and cost-effectively. ProMIS' lead candidate
antibody, PMN310 for Alzheimer's disease (AD), demonstrates a high
degree of binding to toxic oligomers without binding to non-toxic
forms of naturally occurring amyloid beta protein. The company's
program for Parkinson's disease (PD) is based on the development of
several potential antibody therapeutic candidates aimed at
selectively targeting toxic oligomers of the protein α-synuclein,
considered a root cause of PD. Similarly, ProMIS has identified
antibody candidates selectively targeting toxic oligomers of the
protein TDP43, considered a root cause of ALS.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc.
is a development stage biotechnology company focused on discovering
and developing antibody therapeutics selectively targeting toxic
oligomers implicated in the development and progression of
neurodegenerative diseases, in particular AD, PD and ALS. The
Company's proprietary target discovery engine is based on the use
of two complementary techniques. The Company applies its
thermodynamic, computational discovery platform -ProMIS and
Collective Coordinates – to predict novel targets known as Disease
Specific Epitopes on the molecular surface of misfolded proteins.
Using this unique precision medicine approach, the Company is
developing novel antibody therapeutics for AD, PD and ALS.
ProMIS is headquartered in Toronto,
Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on
the Toronto Stock Exchange under the symbol PMN, and on the OTCQB
Venture Market under the symbol ARFXF.
Visit us at www.promisneurosciences.com or follow us
on Twitter and LinkedIn
The TSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. This information
release contains certain forward-looking information. Such
information involves known and unknown risks, uncertainties and
other factors that may cause actual results, performance or
achievements to be materially different from those implied by
statements herein, and therefore these statements should not be
read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently
available to it as well as other factors. Readers are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by
the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/promis-neurosciences-to-participate-in-the-think-equity-investor-conference-300836054.html
SOURCE ProMIS Neurosciences Inc.